Sector News

Sigma-Aldrich® Acquires Cell Marque To Strengthen Immunohistochemistry Business

October 6, 2014
Life sciences
/PRNewswire/ – Sigma-Aldrich® Corporation (Nasdaq: SIAL) announced today that it has entered into an agreement to acquire Rocklin, California, based Cell Marque Corporation in a move to strengthen its antibody portfolio and to better serve immunohistochemistry (IHC) customers. Cell Marque designs, develops and manufactures antibody reagents and kits, an offering that will complement Sigma-Aldrich’s IHC product family. The Company expects this acquisition to be neutral to mildly accretive to earnings per share in 2015. Terms of the transaction were not disclosed. The transaction, which is subject to regulatory approvals and other customary closing conditions, is anticipated to close by the end of 2014.
 
Cell Marque is well-recognized in IHC for its high quality products and technical expertise, including validated, fit-for-purpose antibodies and IHC staining kits aimed at pathologists and clinicians focused on patient management. The company employs more than 90 people.
 
“We expect that Cell Marque’s strong in vitro diagnostic (IVD) antibody product lines and solid relationships with pathologists and companies that provide automated staining instrumentation will broaden the diagnostic health reach of Sigma-Aldrich,” commented Frank Wicks, Ph.D., President of Sigma-Aldrich’s Applied Business Unit. “Cell Marque’s scientific knowledge and experience in the design, validation and manufacturing of IVD antibodies for immunohistochemistry make them an attractive addition to our business, complementing our workflow solutions aimed at IVD customers. With these products and the scientific expertise behind them, we can build upon our extensive capabilities in this area, providing even greater value to current and new customers alike.”
 
Nora Lacey, President & CEO, Cell Marque said, “I believe that there is great synergy between Sigma-Aldrich and Cell Marque, and being a member of the Sigma-Aldrich family will bring our customers a partner with the depth and breadth of resources to continually innovate and expand upon our product offering. I am convinced that the legacy Cell Marque has created through its dedication and commitment to our customers will be carried on by Sigma-Aldrich into the future as we are all committed to providing customers with unsurpassed quality and service.”
 
Source: Sigma-Aldrich

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach